Experiences with

Farydak

1 public post

MPN News for treatment primary myelofibrosis, post-PVMF, Post ET-MF and Primary myelofibrosis

The combination of panobinostat (Farydak) and ruxolitinib (Jakafi) demonstrated efficacy and a tolerable safety profile as a treatment for patients with primary myelofibrosis (PMF) and post-polycythemia vera–related myelofibrosis (post-PV MF), and post-essential thrombocythemia–related myelofibrosis
mammared profile image
mammared
in MPN Voice
Want to take advantage of all our features? Just log in!
or
    Filter results
    Posted in
    Sort by